Recent 8-K filings for COCP
Highest-materiality recent filing
Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
- Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
- Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.
-
Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin
James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
-
Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988
FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
-
Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988
First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
-
IRB approval from Emory University to initiate Phase 1b human challenge study with CDI-988 for norovirus prevention and treatment.
-
Cocrystal Pharma Reports Q3 2025 Net Loss of $2.0M, Provides Norovirus and Influenza Program Updates
Received FDA IND clearance for CDI-988 as norovirus preventive and treatment; Phase 1b challenge study expected to begin Q1 2026.
-
Cocrystal Pharma closes $4.7M registered direct offering with warrant coverage
Gross proceeds of ~$4.75M from sale of 2,764,710 shares at $1.70 each.
-
Cocrystal Pharma announces up to $13M registered direct offering at $1.70/share
$4.7M upfront from sale of 2,764,710 shares at $1.70; closing expected Sep 15, 2025.
-
CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
-
Net loss for Q1 2025 was $2.3M ($0.23/share) vs $4.0M ($0.39/share) in Q1 2024.
-
CDI-988 demonstrated potent binding to conserved region of GII.17 protease, comparable to activity against GII.4 variants.
-
Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances
Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
-
Cocrystal Pharma extends Phase 2a flu study due to low infection rate, data uninterpretable
No SAEs or drug-related discontinuations in Phase 2a study of oral PB2 inhibitor CC-42344.
-
Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon
Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.
-
Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones
Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.
-
Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set
Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
-
Cocrystal Pharma reports favorable Phase 1 SAD results for CDI-988 oral pan-viral protease inhibitor
CDI-988 showed favorable safety and tolerability in SAD cohorts; doses from 100 mg to 600 mg.
-
Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024
In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
-
Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A
Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
-
Net loss $18.0M ($1.87/share) vs $38.8M ($4.77/share) prior year which included $19.1M goodwill impairment.
-
Cocrystal Pharma gets FDA Pre-IND feedback on oral CC-42344 for influenza A
Received FDA Pre-IND written response to January 2024 submission for oral CC-42344.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event other_material